ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. November 21, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. August 12, 2019
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th Press release Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th August 15, 2018
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 Press release LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 15, 2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 11, 2019
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates August 29, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial Press release Key Updates June 08, 2017
ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC Press release LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 21, 2016
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 26, 2019
ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference Press release LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 24, 2017